EP. 2 Long Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients with Pretreated KRAS G12C-Mutated NSCLC
EP. 3 Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC from the Phase III CROWN Study
EP. 4 KRYSTAL-1: Two Year Follow Up of Adagrasib Monotherapy in Patients With Advanced/Metastatic KRAS G12C Mutated NSCLC
EP. 5 Brigatinib Versus Crizotinib in ALK Inhibitor-Naïve Advanced ALK-Positive NSCLC: Results on Phase 3 ALTA-1L Trial
EP. 6 Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA NSCLC: Updated Results From the Phase III Randomized ADAURA Trial
EP. 7 Amivantamab in EGFR Exon 20 Insertion Mutated NSCLC Progression on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase 1 Study
EP. 8 Association Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC
September 20th, 2026Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.Read more
September 10th, 2026Which Lung Cancer Presentations Will Move the Needle at WCLC 2026?Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.Read more
September 9th, 2026OST-HER2 Yields Significant 3-Year Survival in Pulmonary OsteosarcomaThe interim 3-year OS rates were 71.2% with OST-HER2 vs 45.8% in historical controls in a phase 2b trial of fully resected, pulmonary metastatic osteosarcoma.Read more